Últimos avances en el tratamiento neoadyuvante de cáncer de vejiga

Patricia Rioja; Guillermo Valencia; Zaida Morante; Roberto  Paz; Heberth Vallejos; Hugo Fuentes; Silvia Neciosup

doi:10.35663/amp.2022.391.2201

Patricia Rioja Instituto Nacional de Enfermedades Neoplásicas https://orcid.org/0000-0003-3141-7418
Guillermo Valencia Instituto Nacional de Enfermedades Neoplásicas https://orcid.org/0000-0002-4234-4448
Zaida Morante Instituto Nacional de Enfermedades Neoplásicas https://orcid.org/0000-0001-9725-9278
Roberto Paz Clínica Oncosalud - AUNA. Lima, Perú https://orcid.org/0000-0002-2802-8545
Heberth Vallejos Russian Scientific Center of Radiology and Radiotherapy https://orcid.org/0000-0002-0517-0979
Hugo Fuentes Instituto Nacional de Enfermedades Neoplásicas https://orcid.org/0000-0002-2747-7381
Silvia Neciosup Instituto Nacional de Enfermedades Neoplásicas https://orcid.org/0000-0002-2657-9853

DOI: https://doi.org/10.35663/amp.2022.391.2201

Keywords: Urinary Bladder Neoplasms, Neoadjuvant Therapy, Immunotherapy, Biomarkers

Abstract

Cisplatin-based neoadjuvant therapy has shown clear benefits in clinical stage II or IIIA muscle invasive bladder cancer (MIBC), achieving an impact in progression-free survival and overall survival. This updated review focuses on neoadjuvant therapy for MIBC, including the current recommendations from international and/or local practice guidelines, as well as studies of new therapeutic agents (immunotherapy, targeted therapy), on top of research on potential biomarkers that may predict response to immunotherapy.

Downloads

Download data is not yet available.

Latest advances in neoadjuvant therapy for bladder cancer

Abstract

Downloads

DB Error: Error writing file '/tmp/MYQ1uGN3' (Errcode: 28 - No space left on device)